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Abstract: Introduction: The design of advanced drug delivery systems based on synthetic and su-
pramolecular chemistry has been very successful. Liposomal doxorubicin (Caelyx®), and liposomal 
daunorubicin (DaunoXome®), estradiol topical emulsion (EstrasorbTM) as well as soluble or erodible 
polymer systems such as pegaspargase (Oncaspar®) or goserelin acetate (Zoladex®) represent consider-
able achievements.  
The Problem: As deliverables have evolved from low molecular weight drugs to biologics (currently 
representing approximately 30% of the market), so too have the demands made of advanced drug deliv-
ery technology. In parallel, the field of membrane trafficking (and endocytosis) has also matured. The 
trafficking of specific receptors i.e. material to be recycled or destroyed, as well as the trafficking of 
protein toxins has been well characterized. This, in conjunction with an ability to engineer synthetic, 
recombinant proteins provides several possibilities.  
The Solution: The first is using recombinant proteins as drugs i.e. denileukin diftitox (Ontak®) or 
agalsidase beta (Fabrazyme®). The second is the opportunity to use protein toxin architecture to reach 
targets that are not normally accessible. This may be achieved by grafting regulatory domains from 
multiple species to form synthetic proteins, engineered to do multiple jobs. Examples include access to 
the nucleocytosolic compartment. Herein the use of synthetic proteins for drug delivery has been re-
viewed. 
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1. INTRODUCTION
The aim of this paper is to explore the use of protein ar-
chitecture to mediate drug delivery, borrowing domains and 
motifs of known function to solve problems associated with 
drug bioavailability. There are currently more than 200 bio-
pharmaceutical products on the market, representing a mar-
ket of approximately $70-80 billion (about 30% of all li-
censed marketed drugs) [1, 2]. Unlike many drugs based 
upon small molecules, biopharmaceutics often requires ad-
vanced drug delivery technology to address three limitations 
associated with its use i.e. stability in biological fluids, im-
munogenicity and in vivo half-life [3]. In addition to the 
aforementioned limitations, target compartment accessibility 
is also a significant challenge. However, drugs based upon a 
molecule or supramolecular assembly that have evolved to 
reach normally inaccessible target compartments prove to be 
the exception [4]. This is pertinent to drug delivery as “third 
order”, or organelle-specific targeting remains a significant 
challenge, which is exemplified by the problems associated 
with the delivery of nucleic acid based drugs [4]. Although 
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there are numerous studies highlighting the 
compartmentalisation of cells as a barrier to third order tar-
geting [4], perhaps the most compelling evidence is the eve-
ryday use of a variety of transfection systems in research 
laboratories across the world. 
 These transfection systems are diverse and include: Ac-
tive Motif’s Chariot reagent (for proteins) [5], the Nucleofec-
tionTM (electroporation) systems sold by Lonza [6], the vari-
ous combinations of cationic polymers and lipids (i.e. 
FuGene6®(Roche) [6] or Lipofectamine 2000 (Invitrogen) 
[7]) and the Helios gene gun (BioRad) [8]. In vivo some suc-
cess has been achieved using attenuated, replication deficient 
viruses as transfection vehicles [9], though recently several 
strategies have emerged that require the use of viruses ex  
vivo to transfect cells that are then re-introduced to the pa-
tient. These licensed drugs are summarised in Table 1. 
 As our knowledge of the molecular regulation of homeo-
stasis has increased, so have the number of  “drugable” tar-
gets to treat disease. As many of these targets reside within 
the nucleocytosolic compartment, a  way  into  this  compart-
ment for non-membrane permeant molecules is critical. This 
is especially true for drugs based on nucleic acids which, by 
default, have no direct way of accessing the nucleocytosolic 
compartment [4]. Consequently, to be active, nucleic acid 
“gene” drugs need to cross several barriers that have evolved 
to limit both genomic plasticity as well as the expression of 
exogenous material. Once cellular uptake localises to the 
ultimately destructive endocytic system, there exist only in-
efficient and non-specific opportunities for escaping the en-
docytic compartment [10, 11]. One example might be the 
endocytic escape mechanism, which occurs during “leaky” 
vesicle fusion [10]. Leaky fusion is time-limited, occurring 
either prior to the enzymatic destruction of the drug, or its 
exocytosis. Leaky fusion may also be more prevalent in cells 
kept in exponential growth phase relative to cells undergoing 
regulated growth in vivo. This may be due to there being 
more opportunities for fusion in a rapidly expanding popula-
tion of cells relative to their quiescent in vivo counterparts. 
1.1. Biologics and the Need for Advanced Drug Delivery 
 Since the FDA licensing of Vitravene in 1998 [12], there 
have been a variety of drugs based upon nucleic acids that 
have been approved in the U.S.A., China and Europe [4]. 
These are summarised in Tables 1 & 2. It is of note that the 
licensing of Vitravene was followed by its withdrawal from 
the market in 2001, not because of concerns over safety, but 
because there was not a high enough demand for the product 
[13]. It is of note that UniQure has also not renewed the 
EMA license for the sale of Glybera for similar (i.e. market 
driven) reasons [14]. The recent FDA licensing of eteplirsen 
by Sarepta Therapeutics, was also controversial, though this 
controversy was founded upon the level of dystrophin pro-
tein resulting from treatment, rather than the drug’s clinical 
benefit i.e. the activity of the dystrophin produced [15]. 
 To date, all of the antisense drugs that have been licensed 
have relied on medicinal chemistry to modulate stability 
rather than using a delivery system to enhance cellular pene-
tration [4, 13]. There are pipelined, various innovative deliv-
ery technologies that are currently under evaluation. One of 
the more notable is GalNak conjugated siRNA, developed by 
Alnylam Pharmaceutics [16]. GalNak has been shown to 
very effectively target siRNA to hepatocytes in vivo. What 
was not obvious from the literature was the mechanism that 
GalNak conjugated siRNA utilized to exit the membrane-
bound endocytic system and access the nucleocytosolic 
compartment after internalisation.  There is published evi-
dence that this delivery system increases siRNA efficacy in 
vivo by up to 5-fold [16]. However, without a mechanism to 
effect siRNA liberation from the constraints of the endocytic 
system, it is possible that this system is reliant upon “leaky” 
vesicle fusion as a means of cytosolic entry. This conundrum 
is highlighted when the toxicity of non-membrane permeant 
protein toxins requiring cytosolic translocation is considered. 
Ricin toxin (RT) depurinates ribosomal RNA at the 
ricin/sarcin loop, inhibiting protein synthesis. To exert this 
effect RT a-chain (RTAC) needs to access the cytosol and to 
then interact with ribosomes [17]. When ricin holotoxin’s 
(i.e. RT a- and b-chain) toxicity was compared with that of 
RTAC alone, several logs less toxicity were recorded relative 
to the holotoxin. This was due to the navigation of the en-
domembrane system afforded by the RT b-chain (RTBC). 
This example highlights the need for the active navigation of 
the endomembrane system if the translocation of large mem-
brane non-permeable molecules is required [4, 17]. 
 Beyond the need for modulation of intracellular 
compartmentalisation, there is also a pressing need to ad-
dress biologics stability in biological fluid, in vivo half-life 
and immunogenicity [3]. Conventional solutions to these 
problems have been addressed using a variety of strategies 
centring on steric inhibition. Well known examples include 
PEGylation [18], which requires the covalent attachment of 
poly(ethyleneglycol) (PEG) to a protein i.e. pegaspargase 
(Oncospar®) [19]; the encapsulation of a drug within a 
liposome such as those used for the formulation of the 
doxorubicin HCl liposome injection (Doxil®) [20]; or the use 
of an erodible polymer matrix to facilitate the controlled 
release of the drug goserelin acetate (i.e. Zoladex®) [21]. 
PEG is extremely hydrophilic and has been reported to im-
part “stealth” properties to conjugated proteins, shielding 
them from both proteases and the immune system [18]. This 
has the effect of extending attributes like plasma half-life and 
Table 1. Gene therapeutic drugs licenced for human use. 
Brand Name Drug Condition Administration 
Market Authorisation 
Holder 
Reference 
Strimvelis 
Autologous CD34+ enriched cell 
fraction that contains CD34+ cells 
transduced with retroviral vector 
that encodes for the human ADA 
cDNA sequence 
Severe Combined Immunodefi-
ciency (SCID) due to Adeno-
sine Deaminase Deficiency 
(ADA) 
Ex Vivo 
Orchard Therapeutics 
B.V. 
[10] 
Kymriah 
Tisagenlecleucel (chimeric anti-
gen receptor T-cell (CAR-T) 
therapy to treat) 
Precursor B-Cell Lymphoblas-
tic Leukemia. Lymphoma. 
Lymphoma, Large B-Cell, 
Diffuse. 
Ex Vivo 
Novartis Europharm 
Limited 
[11] 
Glybera alipogene tiparvovec Hyperlipoproteinemia Type I 
Intra -muscular 
injection 
uniQure biopharma 
B.V. 
[81] 
Gendicin rAd-p53 
Head and neck squamous cell 
carcinoma 
Many including 
IP and IV 
Shenzhen SiBiono 
GeneTech 
[82]
consequently efficacy. A well-cited example of a protein 
benefiting from “stealth” technology is pegaspargase, which, 
similar to insulin, has an extracellular target [19]. However, 
if a (topologically) intracellular target is chosen, another 
level of delivery is required. Two pertinent examples of pro-
tein drugs with intracellular targets are onabotulinumtoxin A 
(Botox®) [21] and denileukin diftitox (Ontak®) [22], both of 
which utilise highly evolved strategies to overcome subcellu-
lar compartmentalisation. 
2. Protein Drugs that Modulate Subcellular Trafficking
Anabotulinumtoxin A (Botox®, Allergan) is the best
known of the protein drugs that can achieve third order tar-
geting [21]. Botox® contains serotoxin A from Clostridium 
botulinum (BoNT). This is marketed under a variety of 
names, and is used to treat a plethora of conditions. Specific 
serotypes of botulinum toxin target specific regions of this 
“soluble N-ethylmaleimide-sensitive factor activating protein 
receptor (SNARE)-pin” forming complex, cleaving their 
target proteins and ablating the release of neurotransmitter 
(i.e. acetylcholine) into the synaptic cleft. Targets include: 
synaptobrevin, syntaxin, synaptosomal-associated protein of 
25 KDa (SNAP-25). SNAP-25 is necessary for neurotrans-
mitter release and is resident upon vesicles (containing neu-
rotransmitter) hemi-fused to the cytosolic leaflet of the pre-
synaptic membrane [23, 24]. Inactivation of this complex 
causes flaccid paralysis of muscles, which can be fatal [23]. 
In order to interact with this family of SNARE related pro-
teins, the botulinum toxins require access to the cytosol, 
which in turn requires it to translocate out of the endomem-
brane system. To this end, the botulinum toxins have evolved 
to encompass not only the catalytic, SNARE interacting le-
thal domains of the light (L) subunit, but also a membrane 
interacting and pore forming heavy (H) subunit [23]. Mem-
brane association is mediated by an interaction between 
polysialoganglioside lipids and synaptic membrane protein 
receptors on presynaptic nerve terminals via the toxin heavy 
chain “C” domain [23]. This interaction facilitates the 
internalisation of the heavy and light chains, connected by a 
disulphide bond. The acidification of endocytic vesicle 
drives a conformational change in the “HN” domain of the 
toxin heavy chain, which mediates membrane insertion, 
oligomerisation and pore formation [23]. The light chain 
translocates over the “HN” pore and the disulphide bond 
connecting the heavy and light chains is reduced, liberating 
the metalloprotease-containing light chain within the cytosol 
[23, 24]. This drug represents a market of close to $2Bn a 
year and underscores the market's acceptance of the use of 
toxins not just as medicines but also for non-life threatening 
cosmetic applications [21, 22]. 
 Denileukin diftitox (Ontak®, Eisai Medical Research 
Inc.) was approved to treat cutaneous T-cell lymphoma by 
the FDA in 1999 [22]. In 2006 the license was reviewed fol-
lowing several reports of adverse events, and a black box 
warning describing the possibility of drug-related vision loss 
was added to the label [25]. Denileukin diftitox was with-
drawn from the market in 2014 [25]. The drug contained a 
recombinant protein derived from both the receptor-binding 
domain of interleukin-2 (IL-2) and diphtheria toxin (DT) [22, 
25]. Given that the IL-2 receptor is overexpressed on the 
target neoplasic cells, it was strategized that this would drive 
enough toxin preferentially into this population of cells to 
produce a therapeutic effect [22, 25]. The diphtheria toxin 
portion of this drug has a similar architecture to the Clos-
tridial toxins previously described [22-24]. DT is a virulence 
factor produced by Corynebacterium diphtheria, and is syn-
Table 2. Antisense and siRNA drugs licenced for routine clinical use. 
Brand Name Drug Condition 
Mechanism of 
Action 
Market 
Authorisation 
Holder 
Modification Reference 
Vitravene Fomivirsen 
Cytomegalovirus retinitis 
(CMV) in immuno-
compromised patients
mRNA destruc-
tion 
Novartis Phosphorothioate [15] 
Kynamro Mipomersen 
Homozygous familial 
hypercholesterolemia 
mRNA destruc-
tion 
Genzyme 
Corporation 
Phosphorothioate ASO 
with 2’-O-methoxyethyl-
modified ribose ends 
[83] 
Spinraza Nusinersen Spinal muscular atrophy Exon skipping Biogen 
Phosphorothioate ASO 
with 2’-O-methoxyethyl-
modified ribose 
[84] 
Eteplirsen Exondys51 
Duchenne muscular dys-
trophy 
Exon skipping 
Sarepta Thera-
peutics Inc. 
Uncharged morpholino 
oligomers 
[17] 
Onpattro Patisiran 
Hereditary transthyretin-
mediated amyloidosis 
siRNA 
Alnylam 
Pharmaceuti-
cals Inc. 
Ribonucleic acid formu-
lated as a lipid complex 
[85] 
Tegsedi Inotersen 
Hereditary transthyretin-
mediated amyloidosis 
mRNA destruc-
tion 
Ionis USA Ltd 
Phosphorothioate ASO 
with 2’-O-methoxyethyl-
modified ribose 
[86]
thesized as a single 535 amino acid precursor. This precursor 
is cleaved to form DT-A and -B chains, linked by two disul-
fide bonds, with the DT-B chain containing both trans-
membrane and receptor-binding domains [22, 25]. The DT-A 
chain contains the catalytic domain responsible for inducing 
cell death. The wild type DT-B receptor-binding domain 
interacts with the heparin-binding epidermal growth factor 
precursor receptor, driving toxin internalization and endoso-
mal translocation. The nucleation of multiple transmembrane 
domains in response to the acidification of the endosome 
favors their partitioning into the vesicle-limiting membrane, 
forming a pore. It is through this pore that the catalytic do-
main of the DT-A chain translocates into the cytoplasm. 
Once in the cytosol the DT-A catalytic domain exerts intoxi-
cation by inhibiting protein synthesis, which is achieved 
through the deactivation of elongation factor (EF)-2 [22, 25]. 
Consequently, this drug is an example of a recombinant 
“synthetic” protein engineered to perform a series of specific 
tasks.  Further, it has been engineered to take advantage of 
specific protein architecture responsible for both hijacking 
the endocytic system and mediating endocytic 
“decompartmentalisation”, thus traversing intracellular barri-
ers i.e. membrane. 
2.1. Lysosomal Storage Diseases (LSDs) 
 Represent a grey area within the context of large mole-
cules manipulating membrane trafficking processes. From a 
topological perspective, the lysosome, a depot responsible 
for enzyme storage (as opposed to catalysis, which occurs 
within the endolysosome), may be thought of as being out-
side of the cell [26]. Lysosomal accessibility requires no 
compartmental barriers to be traversed and is therefore fac-
ile. The challenges from a drug delivery perspective lie in 
keeping delivered material intact and at an appropriate con-
centration within the endolysosome [27].  The efficiency of 
endocytic capture should not be overestimated especially if 
fluid phase capture is to be used. This is exemplified in vitro 
through the use of endocytic probes labelled with the fluoro-
phore Texas Red. If Texas Red-labelled Bovine Serum Al-
bumin (BSA) is chased into squamous epithelial cells grow-
ing on coverslips, a concentration of 5-10 mg/mL of BSA  
must be used in order to obtain a robust late endocytic signal 
after a 4h pulse and a 20h chase, even in the presence of 
200µM leupeptin [28]. In contrast, robust late endocytic 
labelling using Texas Red-labelled Wheat-Germ Agglutinin 
(WGA) can be obtained with the same pulse and chase con-
ditions but using a concentration of only 5µg/ml [29]. This is 
because the majority of the BSA will enter the cell using 
(inefficient) fluid phase capture, whereas WGA will bind 
to N-acetyl-D-glucosamine and sialic acid residues, which 
are abundant membrane constituents, and are subsequently 
internalised [30, 31]. 
 Access to endolysosomes (also called the late en-
dosome/lysosome hybrid organelle) and lysosomes may be 
enhanced (relative to fluid phase endocytosis) via an interac-
tion between the deliverable (i.e. a replacement enzyme) and 
the mannose-6-phosphate receptor (M-6-PR). The M-6-PR 
has a somewhat circuitous trafficking pathway, cycling be-
tween the Golgi and the late endosome directly or via the cell 
surface. The M-6-PR exists in two forms, the larger 
(~300KDa) cation-independent (ci) M-6-PR and the smaller 
(~46KDa) dimeric cation-dependant (cd) M-6-PR (~46KDa); 
and both recognise manose-6-phosphate residues present 
upon glycosylated lysosomal proteins [32]. Although Golgi 
to late endosome trafficking is mediated by a di-leucine 
acidic cluster motif, about 10-20% of the M-6-PR population 
has been found at the cell surface. This surface localisation 
of the receptor is believed to provide a scavenger function by 
retrieving enzymes miss-sorted into the secretory pathway 
[32]. It is this function that is of interest here as it can be 
utilised to mediate efficient late endosomal localisation rela-
tive to fluid phase capture. 
 Notable LSDs treated clinically using Enzyme Replace-
ment Therapy (ERT) include Fabry disease [33] and Gaucher 
disease [34]. Fabry disease is caused by a deficiency in α-
galactosidase A and can, over a period of many years, lead to 
the intracellular accumulation of glycosphingolipids [33]. 
This accumulation of glycosphingolipids can cause renal 
failure, cardiomyopathy, and cerebrovascular accidents. This 
condition can usually be treated with agalsidase beta (Fabra-
zyme®), a recombinant human α-galactosidase A produced in 
Chinese hamster ovary cells by the Genzyme Corporation 
[35].  
 Gaucher disease is caused by a deficiency in glucocere-
brosidase (i.e. glucosylceramidase) production [34]. Here 
mutations render the enzyme sub-optimally active, leading to 
the accumulation of glucocerebroside, a membrane compo-
nent of blood cells. This presents clinically as joint pain (of-
ten in hips and knees), hepatomegaly, splenomegaly as well 
as impaired cognition [34]. Treatment options include: 
imiglucerase for injection (Cerezyme®), containing recombi-
nant human β-glucocerebrosidase, made by the Genzyme 
Corporation, for type 1 Gaucher disease [36]; and 
taliglucerase alfa (Elelyso®) made by Pfizer, containing re-
combinant glucocerebrosidase made using plant cells (i.e. 
carrot root cell cultures) [37]. In addition to the above, over 
50 different conditions have been identified and a detailed 
description is beyond the scope of this review [38]. From the 
perspective of this review, the mannosylation of these en-
zymes is of particular interest as it drives endocytic internali-
zation via the M-6-PR, enabling a more efficient receptor 
mediated capture of these recombinant molecules, relative to 
inefficient fluid phase capture of other cargo i.e. ERT [39]. 
3. Strategies to Evade Endolysosome Destruction
Several families of protein toxin have been shown to
evade lysosomal destruction via their manipulation of the 
endomembrane system in order to facilitate access to specific 
intracellular compartments. Some well-known examples are 
listed below and include: 
 RT, a well-characterised binary toxin composed of the 
catalytically active RTAC and a membrane interacting 
RTBC held together by a disulphide bond [40]. RTBC is 
known to bind to both glycoproteins and glycolipids with 
terminal galactose residues and as a consequence it is taken 
into the cell by the activities of various coat proteins such as 
caveolin and clathrin [40]. 
 Golgi translocation occurs from both the rat sarcoma in 
the brain (rab)5 positive early sorting endosome [40] and the 
rab11 positive recycling endosome [40]. Translocation from 
endosome to Golgi has been shown to be relatively ineffi-
cient, accounting for approximately 5% of internalised toxin 
[41] and results in the trafficking of the holotoxin via a rab6a 
positive route [42]. Further, the requirement of PI3P and 
hVps34 as well as sorting nexin 2 and 4 have been shown to 
be critical for RT endosome to Golgi transport [43]. Rab9-
mediated translocation from the late endosome to the Golgi 
has been shown to be redundant during ricin intoxication 
[41]. From the Golgi the holotoxin follows a retrograde route 
to the ER utilising several possible “carriers” such as cal-
reticulin, which cycles between the ER and the Golgi 
utilising a  COP-1 dependant mechanism [44]. Unlike some  
of the AB5 toxins detailed subsequently, ricin displayed no 
obvious ER retrieval motif such as a C-terminal KDEL or 
RDEL motif [45]. From the lumen of the ER the A  chain  
dislocates from the b-chain and has been documented to 
translocate through the Sec61p translocon into the cytosol 
[46], where the RTAC depurinates the ribosomal ricin-sarcin 
loop, inhibiting elongation factor-1 binding, inhibiting pro-
tein synthesis and consequently triggering apoptosis [46].
This rather circuitous route to the cytosol is rather ineffi-
cient and the inclusion of a C-terminal KDEL motif in frame 
with the RTAC significantly increases the molecules’ toxic-
ity [45]. Similarly, moving from the reducing environment of 
the ER lumen to the oxidising environment of the cytosol  
provides the opportunity for dislocation of the a-chain [46]. 
From the perspective of drug delivery, it is also worth com-
menting on the efficiency of the catalytic activity of the ricin 
a-chain, which has been reported to depurinate ribosomes  
faster than they can be synthesised. Given the paucity of 
lysine residues with a-chain, the possibility of ubiquitinyla-
tion and destruction by the proteasome can’t be discounted. 
However, this casts a shadow upon the idea that one mole-
cule of cytosolic ricin is enough to kill a cell [47]. That said, 
the very high activity of the RTAC also hints at the ineffi-
ciency of the navigation of the endomembrane system by this 
toxin.
The AB5 family of toxins includes cholera toxin (CTx),  
shiga toxin (STx) and pertussis  toxins (PTx) [48]. The AB5 
toxins are slightly more complex than RT, having a 
pentomeric assembly of membrane interacting b-chains. This 
pentomer accommodates the  C-terminal region of the cata-
lytically active a-chain via a central aperture. The pentomeric 
b-chain assembly may be homomeric (CTx and STx) or het-
eromeric (PTx) [49]. Like RT, AB5 toxins have been shown  
to traffic from the cell surface with a proportion of 
internalised toxin being trafficked to the Golgi. From  the  
Golgi there  is  a  further  retrograde transport step  to  the  ER  
before the a-chain dislocates and is able to mediate intoxica-
tion via catalytic activity within the cytosol. Once in the ER 
there are several lines of evidence that point to a variety of 
different mechanisms being utilised to exit to the cytosol [4,  
48].
Anthrax toxin (ATx) has three components, the receptor 
and membrane interacting protective antigen (PA), lethal  
factor (LF), which can inactivate mitogen-activated protein 
kinase (MAPK) kinase, and oedema factor (EF), a Ca2+ and 
calmodulin dependent adenylate cyclase [48]. In order for 
the EF and LF to reach their cytosolic targets, intracellular 
membrane barriers need to be crossed. This is achieved via 
the interaction of the PA protein with various cellular com-
ponents. PA is initially synthesised as PA83, an 83KDa pro-
tein. The 20KDa N-terminal is located downstream of 
RKKR furin-like protease recognition motif and its hydroly-
sis triggers PA activation [50]. The dislocation of the PA20 
subunit is thought to act as an immunodecoy and may also 
have toxic properties independent of LF and EF [51]. The 
activated PA can oligomerise into heptamers, or the less 
abundant octamers either in solution or at the cell surface 
after receptor binding [52]. The exact and specific order of 
events is controversial as one report details a lack of furin-
like proteases at the cell surface and another shows that 
PA63 can oligomerise into annular structures in 50% serum 
in the absence of receptors [53]. Further, oligomerisation has 
been documented in serum after the administration of PA83 
in vivo [54]. The three receptors that can recognise, bind and 
internalise PA oligomers are: (i) Tumour endothelial marker 
(TEM)8 [55], (also known as anthrax receptor 1), (ii) Capil-
lary morphogenesis gene (CMG)-2, (also referred to as an-
thrax receptor 2) [56] and (iii) β1-integrin [57]. Early en-
dosome acidification drives a conformational change in the 
PA63n oligomer, extending 2β2s and 2β3s sheets that ulti-
mately form, in the example of a heptamer, a 14-member 
trans-membrane pore [58]. Following internalisation, the PA 
receptor is ubiquitinylated and the whole assembly trafficked 
into microdomains within the early endosome. This mem-
brane is then subject to further deformation and ultimately 
forms vesicles within a vesicle i.e. intraluminal vesicles 
(ILVs). This activity is regulated and mediated by the en-
dosomal sorting complexes required for transport (ESCRT) 
[59]. Once located upon and inserted into the membrane of 
an ILV, the PA63 oligomer mediates the translocation of 
cargo in the form of LF or EF [60, 61], which undergoes a 
molten globular transition [62]. This requires the EF or LF 
N-terminal to bind to the α-clamp [58] on the internal sur-
face of the PA63 oligomer vestibule. Subsequently, further
conformational relaxation of the cargo is mediated by the
dropping pH of the endosome in order for “brownian ratchet-
ing” to move the cargo molecule over the ϕ-clamp and into
the lumen of the ILV [50]. An apoptosis linked gene (ALG)-
2-interacting protein X (ALIX) dependant back-fusion event
between the ILV and the limiting membrane of the multive-
sicular body (MVB) then releases the content of the ILV into
the cytosol [60]. It is of note that after translocation into the
ILV lumen, the LF and EF are effectively protected from
lysosomal hydrolases. Given that the multimeric PA pore is
described as a cation selective channel [58] that requires
cargo to unfold in order to undergo translocation [62], the
observation that supramolecular assemblies containing large
anionic components can traverse the PA pore to access the
cytosol is of direct interest here [53]. Recently published
data describe the cytosolic translocation of both siRNA, an-
tisense oligonucleotides [53], plasmid DNA [62] and plas-
mid DNA polylysine complexes [63], though it should be
noted that plasmid polylysine complexes have been known
to rupture endosomal membranes without anthrax toxin
components [64]. For this to happen one of several things
must be occurring. Firstly, the PA could be weakening,
destabilising or bursting the MVB limiting membrane, which
would be expected to cause toxicity as lysosomal enzymes
would leak into the cytosol [65]. Toxicity was not observed,
yet transfection efficiencies as high as those documented
during nucleofection were reported [62]. Secondly, the su-
pramolecular assembly containing the anionic DNA/ RNA, 
bound to either a LF truncation  (i.e. LFn - also not toxic)  
fused to a DNA (GAL4) or RNA (Protein Kinase R (PKR)) 
binding domain is not unfolding and remaining as a complex 
and the LFn-GAL4/LFn-PKR assembly is translocating 
across the PA pore intact [62]. This means that PA substrates 
do not need to unfold to the extent suggested in the literature. 
Equivalently, a third possibility exists where the LFn-
complex is binding to the PA pore and beginning to unfold. 
This event serves as a “feeder mechanism” that drives the 
nucleic acid into the pore, suggesting that not only cations 
but also anions can serve as translocase substrates in this 
instance. Plasmid translocation is a little harder to reconcile 
given the conformation and radius of gyration of a covalently 
closed circular plasmid bound to LFn-GAL4. However, the 
efficiency with which plasmids were moved into the 
nucleocytosolic compartment without the aid of polylysine 
was very low. This paradox is further deepened by the litera-
ture describing other proteinaceous LFn fusions that have  
also been documented as moving through the PA pore. These 
range from antibody mimetics [66] to the catalytic domains 
of other toxins and include RTAC [67] and PEA [68]. What 
is apparent is that this system represents a robust example of 
domains from several proteins being fused together using 
recombinant technology to perform useful tasks such as 
transfection. 
 Both BoNTs and tetanus toxin (TeNT) bind to the pre-
synaptic membrane of cholinergic terminals with sub-
nanomolar and nanomolar binding affinities [23, 24]. As 
discussed, BoNT causes flaccid paralysis whereas TeNT 
causes spastic paralysis and is produced in the wild by Clos-
tridium tetani [23, 24]. Like BoNT, TeNT exerts its intoxi-
cating effects by blocking neurotransmitter release, in this 
instance within the spinal chord. TeNT enters the CNS via a 
synaptic vesicle protein 2 (SV2)-dependent and an SV2-
independent pathway [23, 24]. Upon endosomal localisation 
and in response to the drop in endocytic pH, like BoNT, 
TeNT undergoes a similar conformational change, exposing 
hydrophobic patches that drive membrane insertion of the 
heavy-chain. The heavy-chain N-terminus (Hn) mediates 
membrane translocation and acts after the C-terminus of the 
heavy-chain has undergone receptor binding driving inter-
nalization. TeNT light chain is responsible for the catalytic 
activity i.e. the hydrolysis vesicle associated membrane pro-
tein (VAMP) 7 [23, 24]. Translocation of the light chain oc-
curs after the multimerisation of the Hn domains, forming a 
membrane ion channel. However, exactly where cytosolic 
translocation occurs is somewhat more difficult to rationalise 
as both TEnT and BoNT are known to traffic into small syn-
aptic vesicles which may facilitate neuron-to-neuron toxin 
transmission i.e. to enter the central nervous system [23, 24]. 
 The cholesterol-dependent cytolysin, streptolysin O 
(SLO) represents, along with ATx, one of the few pore-
forming toxins documented to localise to  the  membranes  of  
ILVs [59, 60, 61]. Given the mechanism of action of SLO, 
i.e. like α-haemolysin it  multimerises, punctures the mem-
brane and allows the unregulated movement (i.e. escape)  of  
cellular components to mediate lysis, this is unexpected.  It is 
possible this is an evolutionary artefact, as unlike ATx PA83 
(or 63) there is no apparent functional reason why SLO
should translocate to ILVs [69]. This might be an attempt by 
the cell to partition the toxin into a compartment where it can 
be safely destroyed without causing harm to the cell. What is 
interesting is the differential ubiquitinylation of the two ILV 
translocating toxins. SLO is directly ubiquitinylated [69] 
whereas ATx is palmitoylated (preventing ubiquitinylation) 
[61] and it is the ubiquitinylation of the receptor that is re-
sponsible for PA ILV translocation. This observation sup-
ports the hypothesis that SLO ILV localisation is an attempt
by the cell to clear the toxin with minimal damage.
3.1. Cellular Processes Utilized by Toxins 
The ESCRT machinery consists of 5 complexes [70]. The 
first, ESCRT 0 contains, in metazoans, hepatocyte growth 
factor-regulated tyrosine kinase substrate (HRS) and signal 
transducing adaptor molecule (STAM) proteins. This com-
plex is responsible for recognising ubiquitinylated trans-
membrane proteins (as opposed to soluble cytosolic pro-
teins), which are then enriched upon the membrane early (i.e. 
rab5 positive) endosomes. The ESCRT I complex consists of 
tumour susceptibility gene (TSG) 101, vacuolar protein sort-
ing (Vps) 28, Vps37a, b&c, and Mvb12a, proteins responsi-
ble for cargo selection. The ESCRT II complex (Vps22, 
Vps25 and Vps36) has been reported to be responsible for 
membrane deformation during ILV biogenesis and the 
localisation and enrichment of cargo within proto-ILVs, via 
interaction with HRS and TSG101 [70]. 
ESCRT III consists of Vps2a and b, Vps20, Vps24, su-
crose non-fermenting protein (Snf)7a, b and c, mVps60, 
Doa4-independent degradation (Did)2a and b, Increased So-
dium Tolerance (Ist)1 protein and has been reported to drive 
vesicle scission. Finally, the Vps4 complex (which consist of 
Vps4 and Vta1) has been reported to interact with ALIX to 
regulate ILV recycling and back-fusion events prior to ILV 
digestion following heterotypic lysosomal fusion [70]. These 
complexes are collectively responsible for the ubiquitinyla-
tion (and de-ubiquitinylation), the enrichment of cargo 
within specific membrane microdomains, and the subsequent 
trafficking of that cargo from the plasma membrane into 
endosomes, and from endosomal limiting membrane into 
ILVs, which are ultimately destroyed [70, 71]. From an evo-
lutionary perspective, this process is critical to overcoming 
the topological problems associated with the attenuation of 
signalling from activated mitogenic receptors such as the 
epidermal growth factor receptor [71]. What may be of use 
to the drug delivery community, is a reported handoff of 
material i.e. RNA between the RNA-induced silencing 
(RISC) complex and the ESCRT complex which may be 
responsible for loading miRNA or mRNA into ILVs prior to 
their secretion as exosomes [72]. If an entry sequence could 
be identified and used as a handle it may be used to load 
over-expressed, synthetic cargo into ILVs or exosomes 
whilst in transit prior to delivery to the cytosol of the target 
tissue. However, there remains the problem of exosome tar-
get specificity i.e. targeting the correct cell type. 
4. THE PERSONALISATION OF PRECISION MEDI-
CINE
At apogee, the use of patient’s own cells to make effec-
tive safe medicines is a lofty goal. At perigee, it may be ar-
gued that this has been achieved using the CAR-T technol-
ogy [73] previously described. However, a more attainable 
ambition that still fosters the notion of personalised medicine 
may be to use patient’s cells to deliver or simply hide a drug 
prior to target assimilation. Over the last 30 years, it has be-
come clear that cells “shed” membrane during their everyday 
function. This membrane forms extracellular vesicles (EVs), 
which may be further subdivided into apoptotic bodies’ mi-
crovesicles and exosomes, a characterisation driven by vesi-
cle size [74].  
 Exosomes carry the potential for driving a paradigm shift 
in drug delivery, shielding large therapeutic molecules from 
the immune system, hydrolytic enzymes, scavenger receptors 
on cells such as hepatocytes; or the cells of the reticuloendo-
thelial system that could limit PK-PD, as well as provide a 
way to overcome the topological limitations of the en-
domembrane system i.e.  by facilitating efficient 
nucleocytosolic delivery [75]. However, many rate  limits  
remain and may be thought of as: 1) Efficient drug loading, 
2) Efficient scale-up of production and 3) Regulated cell 
targeting [75]. Drug loading is still a significant rate limit as 
methods such as extrusion significantly alter exosome topol-
ogy during the process [75]. If the topology of proteins nec-
essary for exosome back-fusion after their endocytic uptake 
by the target cells is incorrect, the subsequent cytosolic de-
livery of cargo will probably not happen, leading to the de-
struction of the exosome and its luminal cargo in the 
endolysosome. Similarly, if the overexpression of cargo or 
the overexpression of cargo fused to a motif that directs it to 
an ILV (such as the LAMP/LIMP signalling motif), cellular  
homeostasis may be altered [76]. It has been reported that 
neoplasic cells  producing  exosomes  can  incorporate  
neoplasic signalling miRNA or mRNA, which may be detri-
mental to the recipient cell [77]. Consequently, there is a 
need for biopsy and to expand healthy cells. If this can be 
done using the patients’ own cells, then there is the potential 
for personalised medicine. Although targeting is an issue, 
there may be several potential solutions at hand. The original 
magic bullet hypothesis did not envisage cell specificity be-
ing derived from an advanced drug delivery system but from 
the drug itself. The use of precision medicines such as 
siRNA to interact with extra-genomic sequence i.e. virally  
derived genes such as Ebola Virus RNA-dependent RNA 
polymerase [78] represents an opportunity for targeting and  
limiting off-target effects. If the anti-viral siRNA is delivered 
to an off target i.e. uninfected  cell,  the result should, in  
theory, be of no significance. If this target specificity can be 
combined with exosome specific targeting i.e. as a function 
of the cell type the exosomes were derived from [79], then 
further target specificity may be achieved. There may be, 
hypothetically, a third level of targeting, however this would 
represent modulating exosome ligand expression to take ad-
vantage of receptor expression levels on target cells. Provid-
ing this can be done in a  way that  is  not  detrimental  to the  
patient (i.e. doesn't stimulate a mitogenic receptor in a cancer 
cell population) then the delivery of a personalised, precision 
medicine to a targeted population of the patient’s cells may 
become a reality.
CONCLUSION 
 The availability of targets for intervention increases as 
more is understood about the molecular regulation of cellular 
physiology and its dysfunction leading to pathology. As the 
accessibility of these targets to new generations of high mo-
lecular weight therapeutics is limited, fresh challenges for drug 
delivery emerge. Examples include drug stability, drug PK-PD, 
drug immunogenicity and the ability of the drug to access its 
target i.e. crossing cellular compartmental barriers. Loading 
high molecular weight drugs into exosomes represents a strat-
egy that utilises the body’s own molecular transport system, 
hiding precision medicines based upon proteins and nucleic 
acids from proteases and nucleases as well as the immune sys-
tem. Should the exosomes be derived from healthy cells from 
the patient, the paradigm could further change, embracing 
self/non-self-recognition and the use of a highly personalised 
delivery technology. However, before this can be achieved, safe 
and efficient means to harvest, load and target exosomes with 
these medicines needs to be improved. 
LIST OF ABBREVIATIONS 
ATx = Anthrax Toxin 
ALIX = Apoptosis Linked Gene (ALG)-2-
interacting Protein X 
BoNT = Botulinum Toxin 
(CMG)-2 = Capillary Morphogenesis Gene 
CAR-T = Chimeric antigen receptor T- cell 
CTx = Cholera Toxin 
DT = Diphtheria Toxin 
EF = Elongation Factor 
ESCRT = Endosomal Sorting Complexes Required for 
Transport 
ERT = Enzyme Replacement Therapy 
EVs = Extracellular Vesicles 
HRS = Hepatocyte Growth Factor-regulated Tyro-
sine Kinase Substrate 
Ist = Increased Sodium Tolerance 
ILVs = Intraluminal Vesicles 
LF = Lethal Factor 
LSDs = Lysosomal Storage Diseases 
M-6-PR = Mannose-6-phosphate Receptor
MVB = Multivesicular Body 
EF = Oedema Factor 
PTx = Pertussis Toxins 
PEG = Poly(ethyleneglycol) 
PA = Protective Antigen 
PKR = Protein Kinase R 
rab = Rat Sarcoma in the Brain 
RT = Ricin Toxin 
RTAC = RT a Chain 
RISC = RNA-induced Silencing 
RTBC = RT b Chain 
STx = Shiga Toxin 
STAM = Signal Transducing Adaptor Molecule 
SNARE = Soluble N-ethylmaleimide-sensitive Factor 
Activating Protein Receptor 
SLO = Streptolysin O 
Snf = Sucrose Non-fermenting Protein 
SNAP-25 = Synaptosomal-associated protein of 25 KDa 
SV2 = Synaptic Vesicle Protein 2 
TeNT = Tetanus Toxin 
TEM = Tumour Endothelial Marker 
TSG = Tumour Susceptibility Gene 
Vps = Vacuolar Protein Sorting 
VAMP = Vesicle Associated Membrane Protein 
WGA = Wheat-Germ Agglutinin 
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